Author: Aspargo Labs

New York, April 15, 2025 — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced that Michael Demurjian, CEO & Chairman, will participate in a panel discussion at the American Urological Association (AUA) Innovation Nexus Conference in Las Vegas, Nevada, taking place on April 25, 2025.

Mr. Demurjian will participate in the panel discussion titled “The Good, the Bad and the Ugly: How to Approach Investors” scheduled for 8:05 – 8:50 a.m. PT on Friday, April 25. As CEO of Aspargo Labs – the company behind HEZKUE®, a first-of-its-kind liquid oral sildenafil suspension already on the market in multiple countries – Mr. Demurjian brings a unique perspective on commercializing innovation in urology and successfully raising capital for groundbreaking products. The panel will be moderated by Andrew Cleeland, BS, CEO of Fogarty Innovation, and will feature fellow panelists Ryan Drant, Founder and Director of Questa Capital Management; Duke Herrell, MD, Founder and CEO of Virtuoso Surgical; and Susan Stimson, BS, Managing Director of KCK Medtech. See full details of the panel discussion here.

“Raising capital in the life sciences is not just about having the right science, it’s about knowing how to navigate the full spectrum of investor dynamics. This means mastering your pitch, articulating why you are the most qualified entrepreneur to implement the business plan and being well-versed in your financial metrics,” said Mr. Demurjian. “Over the course of my career, from Medifast (NYSE: MED), to co-founding an oncology company where we raised over $50 million and took the company public on Nasdaq, to now leading Aspargo Labs, I have experienced firsthand what truly resonates with investors. I look forward to sharing real-world insights with fellow entrepreneurs at the AUA Innovation Nexus Conference.”

The AUA Innovation Nexus Conference provides a powerful forum for advancing urologic discovery, offering multiple elements such as discussion forums, mentorship opportunities, networking, idea generation, and expertise sharing from business executives. The conference creates an environment for urologic entrepreneurs to network, learn, and explore innovative solutions that improve patient care.

About Aspargo Labs, Inc.

Aspargo Labs, Inc., is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. The initial focus is a liquid oral sildenafil suspension currently marketed by Aspargo in multiple countries.

For additional information, please visit our website at www.aspargolabs.com.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

For more information:
Aspargo Labs, Inc.
(646) 503-1260
information@aspargolabs.com

Investor & media contacts:
Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
aspargoIR@russopr.com

New York, April 7, 2025 — Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions for delivery in proprietary digitally connected devices, announced the appointments of Jamel Benkreira as General Manager, United Kingdom & Ireland; and Dr. Pallav S. Shah as Director of Regulatory Affairs, Europe. These strategic appointments strengthen the Company’s international leadership team as the Company continues to expand its liquid oral suspension portfolio and global market presence.

“The addition of Mr. Benkreira and Dr. Shah following our recent of appointments of Alvaro Fernandez and Marc Van Unen as General Managers, Spain and Germany, respectively, is a deliberate expansion of our global capabilities at a critical inflection point,” said Michael Demurjian, Chief Executive Officer & Chairman of Aspargo Labs. “Mr. Benkreira’s successful commercialization and sales record in challenging international markets and Dr. Shah’s proven regulatory expertise with complex regulatory submissions directly align with our immediate priorities: accelerating significant sales growth and commercializing oral liquid suspensions in major international markets.”

Mr. Benkreira joins Aspargo Labs with over 22 years of international experience leading commercial teams and launching products across global markets outside the U.S. Before joining Aspargo, Mr. Benkreira held several key positions at Pharming, NV. including Head of Europe, Middle East, and Africa, where he led business strategy for the launch of a rare disease product in the region. His career includes roles at Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare, Pfizer, and Aimmune Therapeutics. He has managed products through their full lifecycle, from pre-clinical development to commercialization, market expansion, and loss of exclusivity. His expertise spans multiple therapeutic areas, including cardiovascular disease, mental health, oncology, respiratory conditions, HIV, peanut allergy and rare diseases. Mr. Benkreira holds a BSc in Biochemistry & Genetics from the University of Leeds, United Kingdom.

 

Dr. Shah brings extensive expertise in regulatory affairs, pharmacovigilance, and medicinal chemistry to Aspargo Labs. Previously, Dr. Shah served as Chief Executive Officer of Cambridge Regulatory Services, where he oversaw regulatory strategy, pharmacovigilance operations, and medical information services. His experience includes managing marketing authorization applications, clinical trial applications, risk-benefit assessments, and ensuring adherence to international regulatory standards. At Cambridge Regulatory services, Dr. Shah successfully obtained marketing authorizations for over 30products in multiple countries. Dr. Shah holds a Ph.D. in Medicinal Chemistry from the University of the West of Scotland, where his research focused on the synthesis and evaluation of novel compounds for the treatment of hormone-dependent breast cancer. He also earned an MSc in Pharmaceutical Science from Kingston University and a B. Pharm in Pharmaceutical Science from Mumbai University. 

About Aspargo Labs, Inc.

Aspargo Labs, Inc., is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. The initial focus is a liquid oral sildenafil suspension currently marketed by Aspargo in multiple countries.

For additional information, please visit our website at www.aspargolabs.com.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

For more information:
Aspargo Labs, Inc.
(646) 503-1260
information@aspargolabs.com

Investor & media contacts:
Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
aspargoIR@russopr.com

Accomplished regulatory affairs veteran to lead company’s global regulatory strategy and drug product development

New York, February 26, 2025 – Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions for delivery in digitally connected devices, announced the appointment of Mario Guralnik, Ph.D. as Chief Regulatory Officer. Dr. Guralnik’s extensive experience in regulatory affairs and drug development will be instrumental in advancing Aspargo’s regulatory strategy and product pipeline as the Company expands its oral suspension portfolio and pursues unique and expedited approval pathways with the U.S. FDA and corresponding regulatory agencies worldwide.

“Mario is the person we need to lead us in driving our regulatory strategy, ensuring compliance with FDA and corresponding health authority regulations, and expanding our pipeline,” said Michael Demurjian, Chief Executive Officer & Chairman. “I collaborated with Mario in the past and have seen firsthand his ability to navigate regulatory landscapes. Mario’s deep understanding of the technical requirements for regulatory approval of new and improved drug products, combined with his entrepreneurial spirit, aligns perfectly with our mission to accelerate oral suspension technologies through expedited approval pathways, including the 505(b)(2) approval route, and expand our presence in global markets.”

Dr. Guralnik commented, “Aspargo Labs’ oral suspension technology combined with its proprietary connected device for dose administration under development addresses critical medical needs and improves the standard of patient care and medication adherence. I have navigated numerous first-in-class products through regulatory approval and see the significant therapeutic benefits of Aspargo Labs’ novel oral suspensions and electronic delivery devices. The industry has stagnated regarding developing new ways to deliver and monitor medications, which is where Aspargo Labs will be disruptive. I look forward to leveraging my experience to enable Aspargo to achieve its goals of introducing therapeutic products to market quickly and efficiently, and in full compliance with health authority regulations.”

Dr. Guralnik brings decades of regulatory affairs expertise to Aspargo Labs, including experience at Amgen where he directed the successful Erythropoietin program, leading to the development of the marketed products EPOGEN® and Aranesp®. As founder of Synergy Research, Inc., Mario navigated numerous clients through successful drug and device regulatory programs, culminating in product approval. His extensive involvement with FDA advisory boards and industry committees has earned him recognition as a thought leader in regulatory affairs. Dr. Guralnik is a frequent lecturer at the Drug Information Association and Regulatory Affairs Professionals Society and serves as a subcommittee member of the Professional Society for Health Economics and Outcomes Research. He holds advanced degrees from the University of California, Los Angeles (UCLA), including a Ph.D. in Cellular Biophysics, Masters’ degrees in Molecular Biology and Computer Science, and a Bachelor of Science in Biochemistry.

About Aspargo Labs, Inc.

Aspargo Labs, Inc. is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. Aspargo’s initial focus is a liquid oral suspension formulation of sildenafil for the treatment of ED, which the Company markets in Europe and the United Kingdom.

For additional information, please visit our website at www.aspargolabs.com.

FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this press release are forward-looking statements, reflecting management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such forward-looking statements are reasonable, management gives no assurance that such expectations will prove to be correct. You should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to the risks inherent in our lack of profitability and need for additional capital; our dependence on third party vendors to manufacture and advance the development of our drug product candidates and digital drug delivery device; the uncertainties inherent in drug product development, attainment of requisite regulatory approvals and launch of new pharmaceutical products; and the potential for litigation with uncertain outcome.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect new events or circumstances or new information obtained after the date hereof, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case except as required by law.

For more information:
Aspargo Labs, Inc.
(646) 503-1260
information@aspargolabs.com

Investor & media contacts:
Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
aspargoIR@russopr.com

Experienced financial leader joins as the company prepares for its public market entry.

New York, January 27, 2025 – Aspargo Labs, Inc., (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions, has appointed Harold D. Tamayo, MBA, MSIE, as Chief Financial Officer. Tamayo’s extensive experience managing the finances of publicly traded life science companies in the global healthcare sector will be instrumental in shaping Aspargo Labs’ financial strategy as it prepares for its next phase of growth and a planned entry into the public markets.

“Harold’s financial expertise and leadership in scaling up high-growth, healthcare companies are an invaluable addition to Aspargo as we enter this transformative period,” said Michael Demurjian, CEO of Aspargo Labs. “His proven ability to optimize financial operations and align resources with strategic goals will be critical to our success as we work to bring our innovative oral suspension technology to global markets, beginning with our innovative and disruptive sildenafil formulation.”

Tamayo said, “I am thrilled to join the forward-thinking team at Aspargo Labs. The company’s commitment to delivering accessible and patient-friendly formulations addresses critical needs in healthcare.  My focus will be on supporting Aspargo’s growth by leveraging my financial expertise and collaborating closely with this exceptional team. Together, we aim to advance the company’s innovative technology, drive meaningful progress in drug delivery and medication adherence, and create lasting value for patients, partners and stakeholders.”

Tamayo brings extensive experience in leading global financial operations, including licensing, mergers and acquisitions, IPO readiness, Sarbanes-Oxley and SEC compliance. Most recently, he served as Chief Financial Officer and Advisor at a multi-state pharmacy chain with a national reach offering high-touch, boutique service at scale, where he spearheaded strategies that resulted in double digit revenue and EBITDA growth. Prior to this position, Tamayo was Vice President of Finance (FP&A) and Investor Relations and a member of the Senior Leadership Team at Axogen Inc., where he helped develop a comprehensive financial strategy, which contributed to over 20% revenue growth, the company’s first EBITDA-positive quarter after going public, and more than doubled its market capitalization. Tamayo also served as CFO of McKesson Prescription Technology Solutions and SEC-reported segment, CFO of CVS Omnicare and CFO of Express Scripts International. Also, he served in leadership positions with Novartis Pharma and Merck & Co. Tamayo earned his MBA in Finance and M.S. in Industrial Engineering from the University of Miami, and a B.Sc. in Electrical Engineering from Florida International University.

About Aspargo Labs, Inc.

Aspargo Labs, Inc., is a specialty pharmaceutical and MedTech company focused on converting the world’s most meaningful medications into liquid oral suspensions delivered via a proprietary, digitally connected device. Aspargo Labs’ suspension technology offers several key advantages, including improved absorption, ease of administration, flexible dosing, and improved patient adherence. Aspargo is leveraging its unique technology platform to transform a wide range of medications across various therapeutic areas. The initial focus is a liquid oral sildenafil suspension currently marketed by Aspargo in multiple countries.

For additional information, please visit our website at www.aspargolabs.com.

FORWARD-LOOKING STATEMENTS

All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

For more information: Aspargo Labs, Inc. (646) 503-1260 information@aspargolabs.com Investor & media contacts: Russo Partners Nic Johnson or Liz Phillips (347) 956-7697 AspargoIR@russopr.com

NEW YORK, December 20, 2024 – Aspargo Labs, Inc. (“Aspargo Labs” or the “Company”), a specialty pharmacy and MedTech company focused on reformulating the world’s most meaningful Rx and OTC medications into its novel oral suspension technology, announced the recent appointment of two highly experienced General Managers to accelerate Aspargo Labs’ global expansion: Álvaro Fernández in Spain and Dr. Marc van Unen in Germany.

“It is my pleasure to welcome Álvaro and Marc to the Aspargo Labs leadership team,” said Michael Demurjian, Chief Executive Officer. “What we’re building here is quite unique, and these are exactly the type of seasoned leaders we need to drive our international expansion. Álvaro’s expertise in pharmaceutical marketing and sales leadership will be instrumental in developing our presence in Spain, while Marc will leverage his experience launching innovative healthcare products to spearhead our German initiatives. Both represent strategic additions to our team and bring a high level of operational acumen and industry experience that will help us to scale our operations efficiently while prioritizing innovation. Their track records of building successful teams and driving revenue growth align with our mission as we become a global player in medication delivery technology.”  

Álvaro Fernández, the General Manager of Spain at Aspargo Labs, is a pharmaceutical industry veteran with 23 years of experience, leading companies including Lilly, Orion Pharma, Biowise Pharmaceuticals, Angelini, Merck KGaA, and Ferring. His expertise spans across Marketing and Sales leadership roles, where he has demonstrated success in managing multidisciplinary teams and executing high-impact projects. He holds a BA in Biology and Biotechnology from the University of Madrid, an Executive MBA from IE Business School, and completed the Management Development Program at IESE Business School. His leadership approach emphasizes innovation, collaboration, and excellence, consistently driving organizational growth and success.

Dr. Marc van Unen, the General Manager of Germany at Aspargo Labs, has extensive experience in the pharmaceutical industry across a range of products and therapeutic indications. Previously, Dr. van Unen worked at Bristol Myers Squibb, where he led the cardiovascular business unit. He is the former VP of Regional Marketing in Asia for Bayer’s General Medicine portfolio. Through positions at Bristol Myers Squibb and Bayer, Dr. van Unen gained extensive international experience in the US and England, accumulating over 25 years of experience across various therapeutic areas including cardiovascular & central nervous system medicine, urology, hormone, and antibiotic treatments. Dr. van Unen is a visiting lecturer at the Vienna University of Economics and Business and has authored “Product Launch Playbook – introducing new products in the innovative healthcare industry”. He is also an active member of the European International Business Academy. He received his degree in economics from Erasmus University in Rotterdam and his doctorate in International Business Administration from the Bradford School of Management in England.

About Aspargo Labs, Inc.
Aspargo Labs, Inc., is a commercial stage, specialty pharmaceutical and MedTech company focused on advancing administration of medications through innovative oral spray technology and developing a smart delivery system integrated with a mobile platform to connect patients and caregivers. Aspargo Labs’ technology platform has the potential to transform a wide range of medications across various therapeutic areas, with an initial focus on bringing an oral spray formulation of sildenafil to market. By converting solid dose medications into convenient, easy-to-administer oral suspensions, Aspargo Labs’ technology offers several key advantages, including enhanced drug delivery, patient-centricity, dosing flexibility and more personalized medicine. Aspargo Labs is the US and international licensee of the patent rights covering Sildenafil Oral Suspension from Farmalider, S.A. of Madrid, Spain (www.farmalider.com). For additional information, please visit our website at aspargolabs.com

FORWARD-LOOKING STATEMENTS
All statements other than statements of historical facts contained in this press release are forward-looking statements. Forward-looking statements reflect management’s current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as “will,” “expect,” “intend,” “plan,” “potential,” “possible,” “goals,” “accelerate,” “continue,” and similar expressions identify forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; and the outcome of pending or future litigation or arbitration.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

For more information:

Aspargo Labs, Inc.
(646) 503-1260
AspargoIR@russopr.com

Investor & media contacts:

Russo Partners
Nic Johnson or Liz Phillips
(347) 956-7697
AspargoIR@russopr.com